Can I Take Folate With Brisdelle (Paroxetine 7.5 mg)?

What Brisdelle Actually Is, and Why Women Use It

Brisdelle is the only FDA-approved non-hormonal prescription treatment specifically indicated for moderate-to-severe vasomotor symptoms of menopause. It contains paroxetine at a very low dose of 7.5 mg, which is meaningfully lower than the antidepressant doses of paroxetine (20-60 mg) prescribed for depression or anxiety. That dose distinction matters for safety and side-effect profiles.

Paroxetine belongs to the selective serotonin reuptake inhibitor (SSRI) class. In the hypothalamus, serotonin signaling modulates the thermoregulatory set point. During perimenopause and post-menopause, declining estrogen narrows the thermoneutral zone, making the body trigger sweating or shivering at smaller temperature changes. Paroxetine broadens that zone again without the need for hormone therapy.

Who Gets Prescribed Brisdelle

Women who cannot or choose not to use hormone therapy (HT) are the primary candidates. This includes women with a personal history of hormone-sensitive breast cancer, those with contraindications to estrogen, and women who prefer a non-hormonal option on principle. The Menopause Society (formerly NAMS) 2023 position statement on non-hormonal therapies lists paroxetine as having the best evidence base among SSRIs for vasomotor symptoms.

The SYMPHONY Trial Numbers

The key phase 3 SYMPHONY trial showed that women taking Brisdelle 7.5 mg experienced a mean reduction of approximately 5.0 moderate-to-severe hot flashes per day compared with a reduction of approximately 3.9 per day in the placebo group. That difference was statistically significant. The trial enrolled perimenopausal and postmenopausal women, meaning the data directly reflects the population most likely to be prescribed this drug.

What Folate Is and Why Menopausal Women Take It

Folate is a water-soluble B vitamin that plays roles in DNA synthesis, one-carbon metabolism, and amino acid conversion. Women most commonly hear about it in the context of pregnancy, but there are several reasons menopausal women reach for folate supplements too.

Folate and Cardiovascular Risk After Menopause

Estrogen loss accelerates the rise in homocysteine, a sulfur-containing amino acid linked to cardiovascular risk. Folate, along with vitamins B6 and B12, drives the remethylation pathway that converts homocysteine back to methionine. Post-menopausal women have higher mean homocysteine concentrations than premenopausal women of similar age, and some clinicians recommend folate to help manage this.

Folate and Mood During Perimenopause

Folate is a cofactor for the synthesis of serotonin, dopamine, and norepinephrine. Low folate status has been associated with depressive symptoms in several observational studies, and one small randomized trial found that adjunctive L-methylfolate improved depression scores in adults with inadequate antidepressant response. For a woman taking an SSRI-class drug like Brisdelle, optimizing folate status may theoretically support the same serotonin pathway the drug is acting on, though direct trial evidence in the vasomotor-symptom context is thin.

Folic Acid vs. Methylfolate: Which Form Matters?

This distinction is clinically relevant, especially if you carry an MTHFR variant.

• Folic acid is the synthetic, oxidized form found in most supplements and fortified foods. It must be converted by the enzyme MTHFR (methylenetetrahydrofolate reductase) to 5-methyltetrahydrofolate (5-MTHF) to be biologically active.
• 5-MTHF (methylfolate) is the active, circulating form. It bypasses the MTHFR conversion step entirely.

Roughly 10-15% of people of Northern European descent carry the MTHFR C677T homozygous variant, which reduces enzyme activity by up to 70%. If you are homozygous for C677T or compound heterozygous, taking folic acid may leave you with inadequate active folate despite apparently normal serum folate levels. Methylfolate (sold as Quatrefolic, Metafolin, or simply "5-MTHF") sidesteps this problem.

Is There a Drug Interaction Between Folate and Brisdelle?

The short answer: no clinically significant pharmacokinetic interaction exists between folate and paroxetine at any dose.

Pharmacokinetic Interaction: Absorption, Metabolism, Elimination

Paroxetine is metabolized primarily by CYP2D6, with minor contributions from CYP3A4. Folate does not inhibit or induce CYP2D6 or CYP3A4. Folate is absorbed in the jejunum via the proton-coupled folate transporter (PCFT) and the reduced folate carrier (RFC). Paroxetine absorption occurs through passive diffusion in the gastrointestinal tract and does not compete with folate transporters. There is no evidence in the pharmacokinetic literature that folate alters paroxetine plasma concentrations or that paroxetine alters folate absorption or retention.

The Natural Medicines Therapeutic Research database rates the folate-paroxetine combination as having no documented interaction. The FDA prescribing information for Brisdelle does not list folate or B vitamins among known drug interactions.

Pharmacodynamic Consideration: Serotonin Pathway Support

This is where some nuance exists, though it is not an adverse interaction. Folate supports the synthesis of serotonin by providing the methyl groups needed in one-carbon metabolism, which ultimately enables the conversion of tryptophan to serotonin. Paroxetine prevents the reuptake of serotonin from synapses. These two mechanisms are complementary rather than opposing.

The theoretical concern would be serotonin syndrome, but serotonin syndrome from SSRIs typically requires a second serotonergic drug with a distinct mechanism (such as a monoamine oxidase inhibitor or a serotonin releaser like MDMA). Folate supplementation does not raise synaptic serotonin concentrations in a way that has been reported to contribute to serotonin syndrome. The clinical literature on serotonin syndrome does not identify folate or B vitamins as precipitating agents.

Where Anticonvulsant Context Comes From

You may have read that folate is "needed with anticonvulsants." That context applies to drugs like phenytoin, carbamazepine, and valproate, which deplete folate by inducing hepatic enzymes and by directly interfering with folate metabolism. Paroxetine is not an anticonvulsant and does not deplete folate by any known mechanism. The anticonvulsant folate warning does not transfer to Brisdelle.

MTHFR, Methylation, and Why This Matters Specifically for You

The interaction between MTHFR status and SSRI response is an area of active research that most competitor articles do not address. Here is a framework for thinking about it.

Step 1: Do you know your MTHFR status? If you have had genetic testing (23andMe, AncestryDNA, or clinical MTHFR testing), check for rs1801133 (C677T) and rs1801131 (A1298C). If you have not been tested, you can ask your clinician for a targeted MTHFR panel, though routine testing is not recommended by the American College of Medical Genetics for the general population.

Step 2: If you carry a variant, choose the right form of folate. For women with one or two copies of C677T, or compound heterozygosity, choosing 5-MTHF instead of folic acid ensures your body can use the supplement regardless of enzyme activity. A typical supplemental dose of 5-MTHF for adults is 400-800 mcg per day, mirroring standard folate recommendations.

Step 3: Recognize that serotonin synthesis depends on methylation. Serotonin synthesis requires SAM (S-adenosylmethionine), which is generated by the methylation cycle that folate fuels. In theory, optimizing folate status, particularly in the active methylfolate form, could support the serotonin pathway that Brisdelle is modulating. Whether this translates to better hot-flash outcomes in real women taking Brisdelle has not been studied in a controlled trial. That evidence gap is real, and you should not expect a measurable benefit on vasomotor symptoms from adding folate to Brisdelle.

Step 4: Homocysteine monitoring if you have cardiovascular risk factors. If you are post-menopausal with additional cardiovascular risk (hypertension, dyslipidemia, family history), baseline plasma homocysteine and B12 levels can help your clinician personalize your folate dose. Target homocysteine is generally below 10-12 micromol/L, though the HOPE-2 trial found that B vitamin supplementation reduced homocysteine without reducing cardiovascular events, tempering enthusiasm for aggressive homocysteine-lowering as a standalone strategy.

Pregnancy and Lactation: A Required Warning for Brisdelle

Brisdelle is contraindicated in pregnancy. This must be stated directly.

Pregnancy

Paroxetine carries an FDA Pregnancy Category D designation, meaning there is positive evidence of human fetal risk. Paroxetine use in the first trimester has been associated with a small absolute increase in the risk of cardiac malformations, particularly ventricular septal defects. A 2007 meta-analysis in Birth Defects Research quantified this risk increase and led to warnings from both the FDA and the European Medicines Agency. Because Brisdelle is specifically indicated for menopausal vasomotor symptoms, the prescribing population is perimenopausal and postmenopausal women, but not all perimenopausal women have fully stopped ovulating. If you are perimenopausal and still have the possibility of pregnancy, use reliable contraception while taking Brisdelle.

Lactation

Paroxetine passes into breast milk. Published lactation data show that infant relative dose is generally low (approximately 1-2% of the maternal weight-adjusted dose), but because the Brisdelle indication does not apply to women who are breastfeeding, combined use is not recommended. If you are postpartum and experiencing significant mood symptoms, different paroxetine formulations or alternative SSRIs with more lactation data (such as sertraline) should be discussed with your clinician.

Contraception Note

Brisdelle does not itself interfere with hormonal contraceptives, but paroxetine is a strong CYP2D6 inhibitor. Hormonal contraceptives that are metabolized by CYP2D6 (tamoxifen is the classic example in a related context) could theoretically be affected by concurrent paroxetine, though this is not the primary concern with standard oral contraceptives. Perimenopausal women on Brisdelle who also take tamoxifen should discuss this combination with their oncologist, as paroxetine may reduce tamoxifen's conversion to its active metabolite endoxifen.

Who This Combination Is Right For, and Who Should Pause

Good Candidates for Taking Folate With Brisdelle

• Post-menopausal women on Brisdelle who want to support cardiovascular and neurological health through folate adequacy.
• Perimenopausal women with known MTHFR variants who want the active methylfolate form rather than folic acid.
• Women with low dietary folate intake (limited green leafy vegetables, legumes, and fortified grains).
• Women whose clinician has identified elevated homocysteine.

Women Who Should Have a Conversation First

• Women in active cancer treatment taking drugs metabolized by CYP2D6, particularly tamoxifen. Here the concern is not the folate but Brisdelle itself.
• Women who are perimenopausal and not using reliable contraception. Confirm pregnancy status before starting Brisdelle.
• Women taking high-dose supplemental folate (above 1,000 mcg of folic acid per day) who have not checked vitamin B12 status. High folic acid can mask B12 deficiency anemia by correcting the macrocytic blood picture while leaving neurological damage to progress.

Practical Guidance: How to Take Both

Timing

No dose-separation window is required between folate and Brisdelle. Unlike some supplements that alter gastric pH or bind drugs in the gut (calcium carbonate is a common example), folate uses a specific transporter system in the small intestine and does not interfere with paroxetine's passive absorption. You can take both at the same time or at different times of day based on your own preference and tolerance.

Brisdelle is typically taken at bedtime, partly because drowsiness is a known side effect and partly because hot flashes that disrupt sleep are a primary treatment target. Many women find taking a B-complex or folate with dinner or at bedtime convenient and consistent.

Dose

• Standard dietary reference intake for folate in adult women: 400 mcg DFE per day.
• Typical supplemental range for post-menopausal women: 400-800 mcg of 5-MTHF or folic acid per day.
• Upper tolerable limit for folic acid (synthetic form only): 1,000 mcg per day from supplements and fortified foods. This limit does not apply to naturally occurring food folate.
• Doses above 1,000 mcg of synthetic folic acid are generally unnecessary and may mask B12 deficiency.

What to Monitor

Ask your clinician to check:

1. Serum folate or RBC folate (reflects tissue stores better than serum).
2. Vitamin B12 (especially if you are over 50, vegetarian, or on a proton pump inhibitor).
3. Homocysteine if you have cardiovascular risk factors.
4. Paroxetine does not require routine drug-level monitoring at the 7.5 mg dose.

Signs That Something Else Is Going On

Folate and paroxetine do not interact, but some symptoms warrant a call to your clinician regardless of what caused them. Contact your care team if you notice:

• New or worsening mood changes, agitation, or unusual restlessness within the first two weeks of starting Brisdelle (early SSRI-class side effects).
• Nausea or dizziness that does not resolve after the first week.
• Hot flashes that are worsening rather than improving after four weeks on Brisdelle (the drug's meaningful effect is typically apparent by week 4 based on the SYMPHONY trial timeline).
• Tingling or numbness in extremities, which may signal B12 deficiency rather than a folate problem.

The Evidence Gap: What Has Not Been Studied in Women

Women were historically underrepresented in pharmacokinetic and supplement-interaction trials. The data supporting the lack of interaction between folate and paroxetine is largely inferred from their separate pharmacological profiles rather than from a dedicated trial in menopausal women taking both together. No randomized controlled trial has evaluated whether methylfolate supplementation improves Brisdelle's efficacy on hot flashes, mood, or sleep in perimenopausal or post-menopausal women. That trial has not been done. The MTHFR-SSRI interaction literature is largely from psychiatric populations using full antidepressant doses, not the 7.5 mg menopausal dose. Extrapolation from higher-dose psychiatry data to this population is reasonable but not proven.

The Menopause Society acknowledges that non-hormonal supplement evidence for vasomotor symptoms is generally low quality. Folate is not listed as a first-line or even evidence-supported supplement for hot flash reduction. Its role alongside Brisdelle is as a general health maintenance supplement, not as a hot-flash treatment.